ArticleJournal of nanobiotechnology2025
Ergosterol-loaded brain-targeted liposomes attenuate stroke via gut microbiota-metabolite-brain axis modulation.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Ischemic stroke lacks effective neurorestorative options. We developed a lactoferrin-guided, long-circulating liposomal formulation of ergosterol (Erg) to enhance brain delivery and probed its mechanism along the gut-brain axis. The liposomes exhibited oxidative microenvironment-accelerated destabilization and drug release under H₂O₂ exposure, thereby enhancing brain accumulation and therapeutic efficacy. In rodent models, Erg liposomes preferentially accumulated in the brain, reduced infarct burden, suppressed neuroinflammation and apoptosis, and improved neurological scores and motor function, which suggests robust functional recovery. Multi-omics correlation analysis indicates that Erg treatment reversed gut dysbiosis and elevated medium-chain fatty acids (e.g., heptanoate), which was spatiotemporally associated with PI3K/AKT/mTOR pathway activation in the brain. Together, these findings support a mechanism whereby Erg promotes recovery via coordinated brain targeting and gut-brain axis modulation, linking microbial metabolite remodeling to pro-survival signaling and highlighting a mechanistically informed strategy for post-stroke neuroprotection.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.